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Postoperative cognitive functions 
in patients with benign intracranial 
lesions
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Claus Zimmer1, Yu‑Mi Ryang2, Florian Ringel2,3 & Jens Gempt2*
The aim of this study was to assess pre‑ and postoperative cognitive functions in patients who 
underwent surgery for benign intracranial lesions. In total, 58 patients (21 men, 37 women, mean age 
51.6 years [range 24–76 years]) with benign intracranial lesions (including benign tumors and vascular 
lesions) and neuralgia of the trigeminal nerve were included in this prospective study. Extensive 
cognitive testing was used to categorize attention, memory, and executive functions. Mood and pain 
were assessed preoperatively  (t0, mean 3.7 days before surgery), immediately after surgery/during 
inpatient stay  (t1, mean 7.6 days after surgery), and at first outpatient check‑up  (t2, mean 99.5 days 
after surgery). All 58 patients were tested at  t0 and  t1, but at  t2 only 24 patients were available at 
 t2. The data were categorized as improvement/stable condition or deterioration and shown as 
percentages. The pre‑ and postoperative values of BDI‑II and mood were compared by the Wilcoxon 
test for paired samples. Binary logistic regression analyses were performed to identify parameters 
influencing cognition in the subgroup of meningioma patients. Immediately after surgery  (t1), the 
percentage of patients with improvement/stable condition was > 50% in all categories in the majority 
of subtests (attention: 12/14 subtests, memory: 11/13 subtests, executive functions: 6/9 subtests). 
Similar results were shown at  t2. Mood and pain did not change significantly after surgery. Factors 
like age, Karnofsky performance status, and tumor volume were not shown as significant influencing 
factors for cognitive functions in meningioma patients. The results of this study suggest that—in 
contrast to neuroepithelial tumors—cognitive functions do not deteriorate after surgery of benign 
intracranial lesions. Further studies are necessary to evaluate the results of this study.
Extensive cognitive testing is not used routinely before or after surgery of intracranial lesions. The main factors 
assessed in clinical routines and in neurooncological studies are age, functional independence (measured by the 
Karnofsky Performance Status Scale  [KPS]1), neurological status, and extent of resection. However, evidence is 
increasing that cognition is important for not only quality of life but also overall  survival2–5. Many studies have 
assessed pre- and postoperative cognitive functions in patients with gliomas and brain  metastases6–11. Several 
studies have also evaluated the effect of meningioma surgery on cognitive  functions12–19. Most of these studies 
have shown preoperative impairment and postoperative improvement of cognition in meningioma patients, 
sometimes with conflicting  results16–18,20. Zweckberger et al.19 reported delayed improvement of cognitive func-
tions, whereas another recent study showed ongoing  impairment21. Little is known about pre- and postop-
erative cognitive functions in patients with rare intracranial tumors or vascular lesions like arterious venous 
 malformations22,23. For unruptured aneurysms, the ISAT trial showed improved cognitive outcomes after endo-
vascular treatment, as compared to a neurosurgical  approach24.
Mood and pain are known to influence  cognition25,26, so these measurements were also included in the study.
The aim of this study was to assess whether cognitive functions, mood, and pain improve or deteriorate after 
surgery in patients with benign intracranial lesions.
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Methods
Study design. The local ethics committee approved this prospective single-center study (clinical trial regis-
tration number 3094/11). All participants signed an informed consent form. The study was conducted in accord-
ance with the ethical standards of the 1964 Declaration of Helsinki and its later  amendments27.
Patient population. Patients who underwent surgery for a benign intracranial process (including benign 
tumors, vascular lesions, and neuralgia of the trigeminal nerve) between September 2012 and December 2014 
were prospectively included in this study.
The data of the preoperative study population and the risk factors for preoperative cognitive impairment 
have been reported  elsewhere28.
The following inclusion criteria were defined: age ≥ 18 years, informed consent, extensive neuropsychological 
testing of pre- and postoperative performance, surgery for a benign intracranial process, preoperative magnetic 
resonance imaging (MRI), knowledge of the German language, no pregnancy, and preoperative Mini-Mental 
Status Examination (MMSE) ≥ 18.
The exclusion criteria included age < 18 years, missing informed consent form, missing postoperative neu-
ropsychological testing, other histopathological diagnosis (e.g., malignant intracranial process), and preoperative 
MMSE < 18.
Study design. Patients were included in this prospective study after detailed information and informed 
consent were obtained. Neuropsychological testing (including the basic test battery [MMSE] and the extended 
test battery [as explained below] was performed at 3 time points by medical students supervised by a certi-
fied neuropsychologist: preoperatively  (t0), immediately postoperatively during inpatient stay  (t1), and during 
follow-up at the first outpatient checkup  (t2).
Basic test battery. The basic test battery was the  MMSE29. This well-known test was used to examine the 
patients’ basic cognitive functions.
Extended test battery. The extended test battery comprised 3 categories of cognitive functions: attention, 
memory, and executive functions. The tests used to evaluate these 3 categories are described below.
Attention. The computer-based Test of Attentional Performance (TAP) was used to evaluate cognitive func-
tions in the attention category (in addition to the TMT-A)30.
Alertness. Reaction times (shown in ms) for visual stimuli were recorded in this subtest, either with acoustic 
notification (alertness W_sound) or without acoustic notification (W_O_sound).
Divided attention. Simultaneous reaction times (ms) to visual (divided attention visual) and to auditory 
(divided attention auditory) stimuli were measured. Furthermore, the numbers of mistakes (divided attention 
failure) and of omissions (divided attention selected) were recorded.
Visual field. Visual stimuli were provided while the patients fixated at a central point. The data (reaction 
time [ms] and omissions [skip]) are shown separately for the right/left and central visual fields.
Trail‑Making‑Test A. The Trail-Making-Test A (TMT-A) task was to connect numbers (1–25) in the right 
order as fast as possible. Time is measured and shown in  seconds31.
Memory. Wechsler Memory Scale (WMS). The Wechsler Memory Scale  Revised32 is a test battery for assess-
ing different aspects of memory and includes 13 subtests. In this study, the block- and digit-span subtests were 
used to evaluate verbal and nonverbal short-term memory. A row of digits was read out, or a group of wooden 
blocks was arranged in a specific order. Patients were asked to repeat the tasks immediately (memory span ver-
bal/nonverbal [ms v/ms nv]) and after a delay (working memory verbal/nonverbal [wm v/wm nv]).
Verbal learning and memory test. The Verbal Learning and Memory Test (VLMT) was used to analyze 
episodic memory. A learning list of 15 words was read out 5 times, and patients were asked to repeat the words 
after the words were read out once (Dg1) and after being read out 5 times (Dg5). The gained knowledge was 
measured (Dg1-5). An interference list with different words was read out, and the patients again were asked to 
repeat the words from the learning list immediately (Dg6) and after a delay of 30 min (Dg7). The loss of knowl-
edge was measured after the interference list was read (Dg5-6) and after a delay (Dg5-7).
Rey Osterrieth complex figure test (ROCF). The well-known neuropsychological Rey Osterrieth Com-
plex Figure Test (ROCF) was used to analyze the patients’ visual memory and visual constructive  capacity33 and 
included 3 subtests. Initially, the subjects were asked to copy a geometrical figure that was shown to them. This 
first subtest was not assessed in the present study. In the next 2, subtests, which were analyzed in this study, the 
subjects were asked to draw a geometrical figure shown to them before, both immediately (ROCF copy) and after 
a 30-min delay (ROCF delay).
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Executive functions. Trail-Making-Test B. The Trail-Making-Test B (TMT-B) was similar to the TMT-A; 
however, the patients were asked to connect letters and numbers in alternation (eg, 1-A-2-B)31. The time needed 
for correct connection was measured in seconds.
Regensburg word fluency test. Formal lexical and semantic fluency was measured by the Regensburg 
Word Fluency Test (RWT)34. Words with a specific initial letter (eg, words beginning with the letter A or L) were 
requested for formal lexical fluency, and words in a specific category (eg, in the category animals) were requested 
for semantic fluency. Another subtest was used to analyze the capability to change between both categories.
Stroop word color test. Color-word interference was analyzed with the Stroop Word Color  Test35. The 
first subtest was word reading, in which the patients were asked to read words (green, blue, etc.) written in black. 
The second subtest was line naming, in which the colors of different lines were recorded. In the third and last 
subtest (interference), patients were asked to read out the color of words that were written in different colors (eg, 
the word “green” was written in blue).
Assessment of mood and pain. Patients’ mood was assessed by the well-known Beck Depression Inven-
tory-II (BDI-II) in 52/58 patients at  t0, in 37/58 patients at  t1, and in 19/24 at  t236. The BDI-II is scored from 0 
to 63, with higher scores for higher extent of depression. The median score of the normative population was 7.4 
(population of n = 582 depressive patients and n = 260 healthy controls, according to the manual of Hautziger 
et al.37 The participants were divided into 5 groups according to scores from the BDI-II: no depression (0–8), 
minimal depression (9–13), slight depression (14–9), moderate depression (20–28), and severe depression (> 28).
Pain, especially headache, in this cohort was assessed using the IBK, the German version of the Headache 
Disability Inventory (HDI)38. This test was available for 43/58 patients at  t0, 33/58 patients at  t1, and 18/24 patients 
at  t2. Pain was divided into 4 scales: no headache, slight headache, moderate headache, and severe headache.
Volumetric measurement. A neuroradiologist performed manual segmentation of the contrast-enhanc-
ing part of the intracranial lesion pre- and postoperatively (iPlan Net Cranial 3.0, Brainlab AG, Munich, Ger-
many). No volumetric measurement was performed of vascular lesions or trigeminal neuralgia.
Surgery. Surgery was performed at the Department of Neurosurgery with the aim of maximum tumor 
resection in patients with benign tumors. Pituitary adenomas were resected using a transnasal-transsphenoidal 
approach, and other benign tumors were resected using trepanation. Aneurysms were treated by clipping and 
pterional trepanation, whereas trigeminal nerve neuralgia was treated by microvascular decompression.
Statistical analysis. IBM SPSS Statistics versions 24.0, 25.0, and 26.0 (SPSS Inc., IBM Corp., Armonk, NY, 
USA) was used for the statistical analysis. Normally distributed data were shown as means/standard deviations, 
and non-normally distributed data were shown as medians/interquartile range (IQR). The delta between the pre- 
and postoperative percentile ranks was recorded, and the patients were divided into improvement/stable condi-
tion or deterioration groups. The Wilcoxon test for paired samples was used for pre- and postoperative compari-
sons of mood and pain and of the basis test battery (MMSE). Binary logistic regression analyses were performed 
to identify risk factors for postoperative changes of cognitive functions. P < 0.05 was defined as significant.
Ethical approval and informed consent. The study was conducted in accordance with the ethical stand-
ards of the 1964 Declaration of Helsinki and its later amendments and approved by the local ethics committee 
(Ethics committee technical university munich). Informed consent was signed by all study participants.
Results
Patient population. Initially, 81 patients were included in the study. Of them, 23 patients were excluded: 
22 patients did not perform neuropsychological testing after surgery due to reduced general condition or lack 
of retrieved informed consent (for further neuropsychological testing after surgery), and 1 patient was excluded 
due to missing surgery (neuroradiological intervention).
Therefore, 58 patients (21 men, 37 women, mean age 51.6 years [range 24–76]) were included in this study, 
with meningioma (n = 23, 19/23 WHO grade I, 3/23 WHO grade II, 1/23 WHO grade III), pituitary adenoma (n 
= 8), vestibular schwannoma (n = 7), neuralgia of the trigeminal nerve (n = 3), cavernoma (n = 3), intracranial 
aneurysm (n = 4), pineocytoma (n = 2), arterial-venous malformation (n = 2), hemangiopericytoma (n = 1, WHO 
grade II), clivus chordoma (n = 1), colloidal cyst (n = 1), subependymoma (n = 1), and others (n = 2). Of the 
58 lesions, 20 were located in the right hemisphere, 23 were located in the left hemisphere, and 15 were located 
in the midline (pituitary adenomas, pineocytoma, aneurysm of the basilar artery, chordoma, subependymoma, 
and 2 meningiomas).
The main tumor locations were the frontal lobe (23/58) and infratentorial region (16/58). The baseline patient 
characteristics also included information about initial symptoms and adjuvant treatment, as shown in Table 1. 
During follow-up (at  t2), 24/58 patients (10 men, 14 women, mean age 46.8 years [range 24–73], with meningi-
oma [n = 8], vestibular schwannoma [n = 3], pituitary adenoma [n = 5], pineocytoma [n = 2], clivus chordoma 
[n = 1], cavernoma [n = 2], aneurysm [n = 1], neuralgia of the trigeminal nerve [n = 1], and others [n = 1]) 
underwent neuropsychological testing. The others either were lost to follow-up or withdrew informed consent. 
The mean time from preoperative testing  (t0) to surgery was 3.7 days (range 1–23 days), the mean time from 
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surgery to postoperative testing during inpatient stay  (t1) was 7.6 days (range 2–55 days), and the mean time 
from surgery to follow-up at the first outpatient control  (t2) testing was 99.5 days (range 61–197 days).
MMSE. No significant differences were observed between preoperative MMSE (29.0 [IQR 28.0–30.0] and 
postoperative MMSE (29.0 [27.0–30.0]; P = 0.278) as well as between preoperative MMSE and follow-up MMSE 
(28.0 [27.3–29.8]); P = 0.522).
Pre‑ and postoperative comparisons. Analyses were performed for all patients and the patients in 
the meningioma and pituitary adenoma subgroups (Table 2). Improvement of cognition was defined as sta-
ble/improving cognitive functions in more than 50% of the patients. In the attention category, 12/14 subtests 
showed early postoperative improvement/stable condition at  t1, as compared to 11/13 subtests in the memory 
category and 6/9 subtests in the executive functions category. Similar results were observed in the subgroup of 
meningioma patients (Table 2). The percentage of patients with improvement during follow-up  (t2) was similar, 
comprising 11/14 subtests in the attention category and, even higher, 13/13 subtests in the memory category and 
9/9 subtests in the executive functions category. Among the meningioma patients, this rate at  t2 was lower in the 
memory category (8/13 subtests). In the subgroup of patients with pituitary adenomas, 12/14 subtests improve-
ment/stable condition immediately postoperatively  (t1) in the attention category, as compared to 7/13 subtests 
in the memory category and 6/9 subtests in the executive functions category. At  t2, 12/14 subtests in the attention 
Table 1.  Patient characteristics classified according to tumor/lesion.




(n=3) Vascular (n=9) Other tumors (n=8)
Age 59.2 years (30–76) 51.1 years (24–68) 55.6 years (38–69) 37.0 years (31–44) 41.8 years (28–61) 43.5 years (30–61)
Sex (female) 18/23 3/8 2/7 3/3 4/9 7/8
Initial symptom
Seizure 2/23 0/8 0/7 0/3 1/9 0/8
Neurological deficit 5/23 2/8 5/7 0/3 2/9 3/8
Pain 3/23 2/8 0/7 3/3 0/9 3/8
Fatigue 2/23 2/8 0/7 0/3 0/9 1/8
Incidental 11/23 2/8 2/7 0/3 6/9 1/8
KPS
t0 100 (90–100) 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 100 (85–100)
t1 100 (100–100) 100 (100–100) 100 (100–100) 100 (100–100) 100 (70–100) 100 (85–100)
t2 100 (90–100) 100 (100–100) 100 (100–100) n/a 100 (100–100) 100 (85–100)
Main tumor location
Frontal lobe 18/23 0/8 0/7 0/3 5/9 0/8
Temporal lobe 3/23 0/8 0/7 0/3 0/9 2/8
Parietal lobe 1/23 0/8 0/7 0/3 1/9 0/8
Mid line 0/23 8/8 0/7 0/3 0/9 3/8
Infratentorial 1/23 0/8 7/7 3/3 3/9 2/8
Ventricle 0/23 0/8 0/7 0/3 0/9 1/8
Hemisphere
Right 12/23 0/8 4/7 0/3 4/9 0/8
Left 10/23 0/8 3/7 3/3 4/9 3/8
Median 1/23 8/8 0/7 0/3 1/9 5/8
Education
Unknown 2/23 0/8 0/7 0/3 0/9 0/8
None 0/23 0/8 0/7 0/3 0/9 0/8
Main school 8/23 4/8 5/7 2/3 3/9 3/8
Secondary school 7/23 1/8 1/7 1/3 4/9 3/8
A-level 6/23 3/8 1/7 0/3 2/9 2/8
Tumor volume
Preoperative volume 7.0  cm3 (2.5–17.5) 2.2  cm3 (0.9–6.7) 3.0  cm3 (0.4–25.7) n/a n/a 0.8  cm3 (0.5–1.4)
Postoperative volume 0.0  cm3 (0.0–0.5) 0.2  cm3 (0.0–0.2) 0.0  cm3 (0.1–0.4) n/a n/a 0.0  cm3 (0.0–0.0)
Recurrent disease, adjuvant therapy
Recurrent disease 5/23 4/8 0/7 0/3 0/9 1/8
Postoperative radiation 
therapy 3/23 0/8 0/7 0/3 0/9 1/8
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category showed improvement/stable condition, compared to 12/13 subtests in the memory category and 7/9 
subtests in the executive functions category (Table 2).
Figure 1 shows the distributions of improvement and deterioration in the subtests of the attention, memory, 
and executive functions categories at  t1 and  t2.
Figure 2 presents the results of the 8 meningioma patients at different time points in each category (attention, 
memory, and executive functions).
Mood and pain. Mood did not change significantly after surgery at  t1 (P = 0.484) and at  t2 (P = 0.306). In 
addition, pain did not change significantly at  t1 (P = 0.060) or at  t2 (P = 0.564). The distributions of depression 
and pain at the different time points are shown in Fig. 3.
Table 2.  Patients with improvement of cognition and/or stable cognition after surgery. Data are shown as 
numbers of patients with improvement/stable condition of cognitive functions in relation to all patients 
performing this subtest immediately after surgery and during follow-up. Improvement > 50% shown in italics.
Test
All patients Meningioma Pituitary adenoma
Improvement stable 
condition at  t1
Improvement stable 
condition at  t2
Improvement stable 
condition at  t1
Improvement stable 
condition at  t2
Improvement stable 
condition at  t1
Improvement stable 
condition at  t2
Attention
Alertness W_O_sound 24/53 (45.3%) 12/24 (50.0%) 7/21 (33.3%) 4/8 (50.0%) 4/8 (50%) 1/5 (20.0%)
Alertness W_sound 23/53 (43.4%) 16/23 (69.6%) 11/21 (52.4%) 6/8 (75.0%) 4/8 (50.0%) 3/5 (60.0%)
Alertness phasic 29/53 (54.7%) 16/23 (69.6%) 13/21 (61.9%) 7/8 (87.5%) 5/8 (62.5%) 3/5 (60.0%)
Divided attention visual 33/53 (62.3%) 18/22 (81.8%) 12/21 (57.1%) 7/8 (87.5%) 5/8 (62.5%) 3/5 (60.0%)
Divided attention 
auditive 27/49 ((55.1%) 12/20 (60.0%) 11/18 (61.1%) 4/6 (66.7%) 5/8 (62.5%) 4/5 (80.0%)
Divided attention failure 33/53 (62.3%) 11/22 (50.0%) 13/21 (61.9%) 4/8 (50.0%) 7/8 (87.5%) 3/5 (60.0%)
Divided attention 
selected 32/53 (60.4%) 13/22 (59.1%) 13/21 (61.9%) 6/8 (75.0%) 5/8 (62.5%) 3/5 (60.0%)
Visual field right 29/51 (56.9%) 13/21 (61.9%) 8/20 (40.0%) 4/7 (57.1%) 6/8 (75.0%) 3/5 (60.0%)
Visual field skip_right 32/51 (62.7%) 11/21 (52.4%) 13/20 (65.0%) 4/7 (57.1%) 7/8 (87.5%) 3/5 (60.0%)
Visual field left 28/50 (56.0%) 13/21 (61.9%) 11/19 (57.9%) 4/7 (57.1%) 6/8 (75.0%) 4/5 (80.0%)
Visual field skip_left 30/51 ((58.8%) 12/21 (57.1%) 12/20 (60.0%) 4/7 (57.1%) 6/8 (75.0%) 3/5 (60.0%)
Visual field central 27/50 (54.0%) 10/21 (47.6%) 12/19 (63.2%) 4/7 (57.1%) 6/8 (75.0%) 3/5 (60.0%)
Visual field skip_central 28/51 (54.9%) 12/21 (57.1%) 10/20 (50.0%) 5/7 (71.4%) 5/8 (62.5%) 2/5 (40.0%)
TMT-A 42/56 (75.0%) 16/20 (80.0%) 14/23 (60.9%) 6/7 (85.7%) 8/8 (100.0%) 5/5 (100.0%)
Memory
WMS ms v 38/57 (66.7%) 19/23 (82.6%) 14/23 (60.9%) 7/8 (87.5%) 6/8 (75.0%) 3/5 (60.0%)
WMS wm v 35/57 (61.4%) 18/23 (78.3%) 13/23 (56.5%) 6/8 (75.0%) 6/8 (75.0%) 3/5 (60.0%)
WMS ms nv 39/57 (68.4%) 18/23 (78.3%) 19/23 (82.6%) 6/8 (75.0%) 4/8 (50.0%) 4/5 (80.0%)
WMS wm nv 31/57 (54.4%) 18/23 (78.3%) 13/23 (56.5%) 8/8 (100.0%) 4/8 (50.0%) 3/5 (60.0%)
VLMT Dg1 34/58 (58.6%) 14/23 (60.9%) 14/23 (60.9%) 5/8 (62.5%) 6/8 (75.0%) 2/5 (40.0%)
VLMT Dg5 35/58 (60.3%) 15/23 (65.2%) 12/23 (52.2%) 4/8 (50.0%) 7/8 (87.5%) 3/5 (60.0%)
VLMT Dg1_5 35/58 (60.3%) 15/23 (65.2%) 12/23 (52.2%) 4/8 (50.0%) 7/8 (87.5%) 3/5 (60.0%)
VLMT Dg6 32/58 (55.2%) 16/23 (69.6%) 12/23 (52.2%) 3/8 (37.5%) 4/8 (50.0%) 5/5 (100.0%)
VLMT Dg7 28/58 (48.3%) 15/23 (65.2%) 11/23 (47.8%) 4/8 (50.0%) 4/8 (50.0%) 4/5 (80.0%)
VLMT Dg5_6 34/58 (58.6%) 15/23 (65.2%) 12/23 (52.2%) 4/8 (50.0%) 4/8 (50.0%) 4/5 (80.0%)
VLMT Dg5_7 24/58 (41.4%) 13/23 (56.5%) 11/23 (47.8%) 5/8 (62.5%) 4/8 (50.0%) 4/5 (80.0%)
ROCF copy 42/56 (75.0%) 21/23 (91.3%) 18/23 (78.3%) 6/8 (75.0%) 7/8 (87.5%) 5/5 (100.0%)
ROCF delay 53/56 (94.6%) 22/22 (100.0%) 21/23 (91.3%) 8/8 (100.0%) 8/8 (100.0%) 5/5 (100.0%)
Executive functions
TMT-B 42/55 (76.4%) 18/20 (90.0%) 19/22 (86.4%) 6/7 (85.7%) 5/8 (62.5%) 5/5 (100.0%)
Stroop’s word reading 29/57 (50.9%) 12/22 (54.5%) 9/23 (39.1%) 5/8 (62.5%) 7/8 (87.5%) 2/5 (40.0%)
Stroop’s naming 28/57 (49.1%) 13/22 (59.1%) 8/23 (34.8%) 5/8 (62.5%) 5/8 (62.5%) 3/5 (60.0%)
Stroop’s interference 31/57 (54.4%) 16/22 (72.7%) 10/23 (43.5%) 7/8 (87.5%) 5/8 (62.5%) 3/5 (60.0%)
Stroop’s failure 45/57 (78.9%) 17/22 (77.3%) 18/23 (78.3%) 6/8 (75.0%) 7/8 (87.5%) 4/5 (80.0%)
RWT lexical 35/58 (60.3%) 18/23 (78.3%) 12/23 (52.2%) 6/8 (75.0%) 6/8 (75.0%) 3/5 (60.0%)
RWT semantic 28/58 (48.3%) 14/23 (60.9%) 9/23 (39.1%) 6/8 (75.0%) 3/8 (37.5%) 5/5 (100.0%)
RWT turning lexical 36/58 (62.1%) 16/23 (69.6%) 15/23 (65.2%) 8/8 (100.0%) 4/8 (50.0%) 2/5 (40.0%)
RWT turning semantic 21/58 (36.2%) 17/23 (73.9%) 8/23 (34.8%) 7/8 (87.5%) 2/8 (25.0%) 4/5 (80.0%)
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Multivariate analysis. For the homogenous subgroup of meningioma patients, binary logistic regression 
analyses were performed with change of cognition after surgery as the dependent variable and age, KPS, and 
tumor volume as the independent variables. Odds ratios (95% CI) are presented in Table 3. No significant influ-
encing factors could be identified in this analysis.
Figure 1.  Proportion of patients with improvement/stable condition and deterioration at  t1 and  t2 in selected 
subtests of the attention (left), memory (middle), and executive functions (right) categories.
Figure 2.  Plots for the 8 meningioma patients in selected subtests of the attention (left), memory (middle), and 
executive functions (right) categories.
Figure 3.  Distributions of mood (BDI-II) and pain before and after surgery.
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Discussion
Cognitive functions in patients with benign intracranial lesions improved or remained stable immediately post-
operatively and during follow-up among the majority of patients in all categories of cognitive functions for the 
cohort of 58 patients. No significant influencing factors, like age, KPS, or tumor volume, were identified for 
changes in cognitive functions among meningioma patients.
The preoperative neurocognitive functions of patients with benign intracranial lesions were analyzed in a 
previous study, which showed that age and KPS were the main risk factors for impaired neurocognitive func-
tions before  operation28. In this study, we analyzed a subgroup of patients with available, extensive postoperative 
neurocognitive testing.
This study showed improvement or stable condition of cognitive functions in the attention, memory, and 
executive functions categories. These results agree with those of Tucha et al., who studied (elderly) meningioma 
patients, showing postoperative improvement mainly in the attention and memory domains and no deterioration 
Table 3.  Binary logistic regression analysis for meningioma patients. Data of independent variables presented 
as odds ratio (95% CI). KPS Karnofsky Performance Status Scale (postoperative values); Tumor volume  (cm3) 
as preoperative volume.
Covariates
Age KPS Lesion volume
Attention
Alertness W_O_sound 1.062 (0.980–1.152) 1.134 (0.926–1.390) 1.039 (0.973–1.109)
Alertness W_sound 1.019 (0.955–10.86) 1.008 (0.907–1.119) 1.003 (0.956–1.053)
Alertness phasic (p) 0.995 (0.932–1.061) 0.865 (0.673–1.113) 0.957 (0.889–1.030)
Divided attention visual (ms) 1.024 (0.959–1.093) 1.023 (0.920–1.138) 0.991 (0.941–1.042)
Divided attention auditive (ms) 1.037 (0.969–1.110) 0.942 (0.768–1.156) 0.981 (0.919–1.048)
Divided attention failure (n) 1.016 (0.952–1.084) 0.975 (0.856–1.111) 1.016 (0.956–1.080)
Divided attention selected (n) 1.013 (0.949–1.081) 0.976 (0.866–1.100) 0.978 (0.929–1.031)
Visual field right (ms) 1.008 (0.941–1.081) 1.024 (0.917–1.143) 1.053 (0.982–1.130)
Visual field skip_right (n) 0.937 (0.848–1.036) 1.035 (0.912–1.176) 0.973 (0.919–1.030)
Visual field left (ms) 1.018 (0.951–1.091) 1.074 (0.939–1.227) 0.987 (0.922–1.056)
Visual field skip_left (n) 0.953 (0.885–1.027) 0.965 (0.862–1.082) 1.015 (0.954–1.081)
Visual field central (ms) 0.977 (0.909–1.050) 1.021 (0.918–1.136) 1.021 (0.953–1.095)
Visual field skip_central (n) 1.000 (0.939–1.066) 1.003 (0.903–1.114) 1.011 (0.962–1.062)
TMT-A (s) 1.015 (0.954–1.080) 0.992 (0.890–1.105) 0.976 (0.926–1.030)
Memory
WMS ms v (p) 0.993 (0.933–1.056) 0.994 (0.894–1.105) 1.002 (0.953–1.053)
WMS wm v (p) 1.007 (0.948–1.070) 0.957 (0.846–1.082) 0.974 (0.924–1.027)
WMS ms nv (p) 0.979 (0.898–1.066) 0.980 (0.836–1.150) 1.027 (0.929–1.136)
WMS wm nv (p) 0.983 (0.922–1.049) 1.038 (0.931–1.156) 1.043 (0.974–1.118)
VLMT Dg1 (p) 1.036 (0.963–1.115) 1.469 (0.916–2.357) 1.102 (0.967–1.256)
VLMT Dg5 (p) 0.927 (0.840–1.023) 5.761 (0.000–n.a.) 1.060 (0.922–1.219)
VLMT Dg1_5 (p) 0.933 (0.862–1.010) 1.026 (0.907–1.160) 1.014 (0.958–1.073)
VLMT Dg6 (p) 0.951 (0.886–1.021) 1.043 (0.918–1.185) 1.023 (0.966–1.083)
VLMT Dg7 (p) 0.958 (0.897–1.024) 1.031 (0.913–1.165) 1.019 (0.965–1.076)
VLMT Dg5_6 (p) 0.963 (0.892–1.040) 1.219 (0.821–1.810) 1.147 (0.999–1.317)
VLMT Dg5_7 (p) 0.976 (0.915–1.041) 1.022 (0.918–1.139) 1.050 (0.977–1.129)
ROCF copy (p) 1.015 (0.940–1.095) 1.054 (0.940–1.183) 0.994 (0.944–1.047)
ROCF delay (p) 3.224 (0.000–n.a.) 8.940 (0.000–n.a.) 0.856 (0.000–n.a.)
Executive functions
TMT-B (s) 1.050 (0.959–1.149) 0.945 (0.691–1.293) 0.950 (0.863–1.047)
Stroop’s word reading (s) 1.063 (0.985–1.147) 1.066 (0.942–1.207) 1.016 (0.962–1.072)
Stroop’s naming (s) 1.013 (0.951–1.080) 1.041 (0.918–1.179) 1.015 (0.964–1.068)
Stroop’s interference (s) 1.067 (0.992–1.148) 1.170 (0.939–1.459) 1.041 (0.972–1.115)
Stroop’s failure (p) 1.100 (0.992–1.220) 1.196 (0.984–1.453) 1.010 (0.947–1.076)
RWT lexical (p) 1.052 (0.984–1.125) 1.171 (0.948–1.446) 1.050 (0.983–1.122)
RWT semantic (p) 0.982 (0.923–1.045) 0.958 (0.861–1.065) 0.978 (0.927–1.032)
RWT turning lexical (p) 1.003 (0.941–1.069) 0.997 (0.881–1.129) 1.048 (0.958–1.147)
RWT turning semantic (p) 1.025 (0.960–1.095) 5.944 (0.000–n.a.) 1.042 (0.930-1.167)
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of preoperative cognitive  functions15,17,39. Another recent study be Meskal et al. showed postoperative improve-
ment in almost all cognitive domains, except for psychomotor speed and reaction  time16.
The mentioned studies by Tucha et al. reported no improvement in executive functions after meningioma 
 surgery17,39. A recent previous study on meningioma patients also reported postoperative improvement of cogni-
tive functions but with lower ongoing cognitive scores as compared to healthy  controls40.
The rate of improvement/stable condition was even higher during follow-up  (t2), as compared to immediate 
postoperative testing  (t1), in this cohort. These results might be explainable by postoperative edema or reduced 
postoperative functional independence (KPS), a known risk factor for cognitive  impairment7. Previous studies 
also showed a transient decline of cognition with recovery at follow-up after surgery and after  irradiation15,19,41. 
The time point when postoperative evaluation occurs might be important for these findings. In this study, the 
first postoperative testing was performed quite early (mean time from surgery to  t1 of 7.6 days). Thus, the afteref-
fects of surgery might be more prominent at this date. In the other mentioned studies on meningioma patients, 
postoperative testing was performed later (about 3 months after surgery), which agrees with our follow-up 
examination  (t2)15,17,39.
However, the results of the follow-up analyses should be taken with caution. According to the study design 
 (t1 = postoperative testing during inpatient stay;  t2 = first follow-up testing on outpatient controls), there were 
major differences in the time periods, with some overlapping results. Furthermore, only patients with a MMSE 
> 18 underwent extensive neuropsychological testing, thus only selecting patients without major deterioration 
after surgery.
The highest rate of improvement/stable condition was observed in the ROCF delay subtest, at almost 100%. 
This improvement might have been because the patients remembered that they had to perform the same task in 
30 min. Therefore, these results should be considered with caution.
In contrast to other studies focusing mainly on 1 entity (eg, meningioma or pituitary adenoma), this study 
included different entities and also vascular lesions. This might introduce a bias due to the high majority of 
the diseases. However, considering a more heterogeneous group could also provide additional information, as 
compared to focusing on only 1 entity.
Among the meningioma patient subgroup, tumor size was not observed as a significant influencing factor, 
contrasting a previous study by Liouta et al.14 These differences might be explained by the different study designs. 
The present study focused on patients with benign intracranial lesions and with therefore had a lower number 
of meningioma patients, whereas Liouta et al. focused only on meningioma patients and therefore had a larger 
number of patients.
The surgical approach and tumor location might affect cognitive functions. Due to the low number of patients 
in the present study cohort, no further analyses were conducted regarding these possibilities. Surgery was per-
formed according to the neurosurgical standards at our department and did not significantly differ between the 
patient subgroups.
This study has several limitations. The high dropout rate during follow-up (at  t2) was a main limitation and 
might have introduced unavoidable bias. Patients with less cognitive deficits might be more likely to perform 
cognitive testing during follow-up than patients with considerable restrictions would. This might have biased the 
results and resulted in overestimation of the rate of patients without deterioration after surgery. Further studies 
with a lower dropout rate are necessary to address this.
Additional limitations include the low numbers of patients with some diseases and the variety of diseases 
included in this cohort. However, subependymoma, clivus chordoma, arterial-venous malformation, and caver-
noma are rare intracranial lesions, and to our knowledge, cognitive functions have not been assessed before in 
patients with these lesions. To address this, a subgroup analysis was performed with meningioma patients only.
In particular, the number of unruptured aneurysms was very low in this cohort (n = 4), and the study does 
not add any new findings to the already known results of the ISAT trial, which showed cognitive improvement 
after endovascular treatment of  aneurysms24.
The study population remains a very heterogeneous population with small numbers of each individual pathol-
ogy. The significance of this study might be limited due to this heterogeneous cohort and many other possible 
confounding variables that would affect cognitive outcomes. However, the aim of this prospective study was to 
include all types of benign intracranial lesions and not to select special subgroups (eg, meningioma patients) as 
previous studies on such cohorts already exist. This exploratory study might draw attention to this heterogeneous 
patient cohort and might be of interest for further (prospective) studies.
Conclusions
Cognitive functions improved or remained stable in the attention, memory, and executive functions categories 
after surgery of benign intracranial lesions in the majority of our cohort of 58 patients. Due to the high dropout 
rate and the various intracranial lesions included in this study, the results of this study should be taken with 
caution, and further studies are necessary to confirm the results.
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